Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AKRO

AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

26.76USD-0.32 (-1.18%)Market Closed

Market Summary

AKRO
USD26.76-0.32
Market Closed
-1.18%

AKRO Alerts

  • 3 major insider sales recently.

AKRO Stock Price

View Fullscreen

AKRO RSI Chart

AKRO Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-10.32

Price/Sales (Trailing)

77.35

Price/Free Cashflow

-11.87

AKRO Price/Sales (Trailing)

AKRO Profitability

Return on Equity

-21.18%

Return on Assets

-19.65%

Free Cashflow Yield

-8.42%

AKRO Fundamentals

AKRO Revenue

Revenue (TTM)

24.2M

Rev. Growth (Yr)

124.95%

Rev. Growth (Qtr)

38.45%

AKRO Earnings

Earnings (TTM)

-179.3M

Earnings Growth (Yr)

-106.51%

Earnings Growth (Qtr)

3.34%

Breaking Down AKRO Revenue

Last 7 days

4.2%

Last 30 days

20.8%

Last 90 days

28.9%

Trailing 12 Months

-39.5%

How does AKRO drawdown profile look like?

AKRO Financial Health

Current Ratio

30.12

AKRO Investor Care

Shares Dilution (1Y)

38.06%

Diluted EPS (TTM)

-3.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202314.0M0024.2M
20220003.9M
20210000

Tracking the Latest Insider Buys and Sells of Akero Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
white william richard
acquired
208,889
7.009
29,803
chief financial officer
Jul 16, 2024
white william richard
sold
-976,274
28.045
-34,811
chief financial officer
Jul 01, 2024
young jonathan
sold
-117,020
23.404
-5,000
chief operating officer
Jun 28, 2024
young jonathan
acquired
21,217
19.941
1,064
chief operating officer
Jun 28, 2024
yale catriona
acquired
21,217
19.941
1,064
chief development officer
Jun 28, 2024
cheng andrew
acquired
21,217
19.941
1,064
president and ceo
Jun 28, 2024
rolph timothy
acquired
21,217
19.941
1,064
chief scientific officer
Jun 28, 2024
lamy patrick
acquired
4,406
19.941
221
senior vp, commercial strategy
Jun 11, 2024
yale catriona
sold
-63,960
22.641
-2,825
chief development officer
Jun 11, 2024
cheng andrew
sold
-178,728
22.641
-7,894
president and ceo

1–10 of 50

Which funds bought or sold AKRO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-24.78
-82,219
190,589
0.03%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
95.38
8,026
17,877
-%
Jul 17, 2024
KBC Group NV
sold off
-100
-38,000
-
-%
Jul 17, 2024
SOA Wealth Advisors, LLC.
unchanged
-
-366
4,762
-%
Jul 12, 2024
SG Americas Securities, LLC
added
191
215,000
341,000
-%
Jul 11, 2024
BOURGEON CAPITAL MANAGEMENT LLC
reduced
-42.57
-178,587
204,102
0.04%
Jul 10, 2024
CWM, LLC
reduced
-56.34
-1,000
1,000
-%
Jul 09, 2024
ZRC WEALTH MANAGEMENT, LLC
unchanged
-
-108
1,408
-%
Jul 02, 2024
GAMMA Investing LLC
added
59.26
327
1,009
-%
Jul 01, 2024
Legal & General Group Plc
added
15.74
253,906
1,261,160
-%

1–10 of 43

Are Funds Buying or Selling AKRO?

Are funds buying AKRO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AKRO
No. of Funds

Unveiling Akero Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
janus henderson group plc
10.1%
6,950,418
SC 13G/A
Mar 15, 2024
general atlantic, l.p.
7.7%
5,233,989
SC 13G
Feb 14, 2024
price t rowe associates inc /md/
6.6%
3,681,209
SC 13G
Feb 14, 2024
pfizer inc
4.53%
2,525,252
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.4%
3,592,759
SC 13G
Feb 14, 2024
redmile group, llc
2.0%
1,109,476
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
4.3%
2,368,378
SC 13G/A
Feb 13, 2024
avidity partners management lp
0.4%
235,000
SC 13G/A
Feb 13, 2024
janus henderson group plc
7.7%
4,306,401
SC 13G/A
Feb 13, 2024
alkeon capital management llc
6.8%
3,764,220
SC 13G/A

Recent SEC filings of Akero Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 01, 2024
144
Notice of Insider Sale Intent
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading

Peers (Alternatives to Akero Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Akero Therapeutics Inc News

Latest updates
American Banking and Market News42 hours ago
Investing.com19 Jul 202402:21 am

Akero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q12022Q42021Q4
Revenue38.5%7,6015,4903,379--
Operating Expenses-3.1%59,95461,87328,75325,42032,439
  S&GA Expenses9.7%9,3048,4816,9667,1004,728
  R&D Expenses-5.1%50,65053,39221,78718,32027,711
Interest Expenses10.5%991897457--
Net Income3.3%-53,344-55,186-25,831-23,059-32,424
Net Income Margin-18.1%-7.40*-6.27*-7.97*-29.01*-
Free Cashflow27.7%-35,140-48,627-24,632-25,508-26,695
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets57.2%91258063566434935737918617019622423825827330011412713815016377.00
  Current Assets62.7%91156057664334735537818416819422223625627129811312613815016377.00
    Cash Equivalents166.4%62423427044425825037417815115116515818818719363.0047.0065.0014816376.00
  Net PPE-5.6%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00------
Liabilities46.8%66.0045.0052.0047.0042.0030.0036.0037.0023.0026.0025.0018.0012.0015.0014.0010.008.009.007.005.002.00
  Current Liabilities58.2%30.0019.0028.0022.0017.0019.0025.0027.0022.0025.0024.0016.0010.0013.0012.0010.008.009.007.005.002.00
Shareholder's Equity58.1%846535583616306327344148147169199220246259286104118129143158-
  Retained Earnings-9.3%-627-574-518-479-448-422-399-363-336-310-277-253-224-209-179-158-142-130-114-99.15-86.56
  Additional Paid-In Capital32.9%1,4741,1091,1031,09675474974351248347947747447146846626226025925825837.00
Shares Outstanding24.0%69.0056.0056.0056.0047.0047.0036.0035.0035.0035.0035.0035.00---------
Float----2,518---340,435---768---478---196-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations27.7%-35,140-48,627-49,719-22,389-24,632-25,508-24,624-19,509-22,876-26,695-14,606-20,034-18,346-23,395-13,508-22,584-11,317-11,649-13,212-5,322-5,444
  Share Based Compensation21.0%7,3986,1165,7394,7984,8444,04011,7314,1613,3112,6422,6122,4362,3641,9161,5461,3231,237670483402215
Cashflow From Investing352.4%57,84912,786-125,697-128,30217,590-101,4453,00011,87022,75012,00021,934-10,65419,00017,899-59,84438,465-6,281----
Cashflow From Financing72995.2%366,938502806336,85515,1532,723217,90034,87713224369.0026624.0059.00202,784100164115-1,60798,200-720
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AKRO Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 50,650$ 21,787
General and administrative9,3046,966
Total operating expenses59,95428,753
Loss from operations(59,954)(28,753)
Interest expense(991)(457)
Interest and other income, net7,6013,379
Net loss(53,344)(25,831)
Net unrealized loss on marketable securities(349)(16)
Comprehensive loss$ (53,693)$ (25,847)
Net loss per share, basic$ (0.9)$ (0.55)
Net loss per share, diluted$ (0.9)$ (0.55)
Weighted-average number of shares used in computing net loss per common share, basic59,307,75946,944,059
Weighted-average number of shares used in computing net loss per common share, diluted59,307,75946,944,059

AKRO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 623,854$ 234,207
Short-term marketable securities279,811315,803
Prepaid expenses and other current assets7,6159,952
Total current assets911,280559,962
Long-term marketable securities 19,283
Property and equipment, net1718
Right of use asset9461,008
Total assets912,243580,271
Current liabilities:  
Accounts payable13,7837,038
Accrued expenses and other current liabilities16,47612,090
Total current liabilities30,25919,128
Loan payable, noncurrent34,80324,964
Warrant liability17854
Operating lease liability, noncurrent750819
Total liabilities65,99044,965
Commitments and contingencies (Note 12)
Stockholders' equity:  
Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 69,148,429 and 55,754,445 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively76
Additional paid-in capital1,473,7651,109,126
Accumulated other comprehensive (loss) income(79)270
Accumulated deficit(627,440)(574,096)
Total stockholders' equity846,253535,306
Total liabilities and stockholders' equity$ 912,243$ 580,271
AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEakerotx.com
 INDUSTRYBiotechnology
 EMPLOYEES44

Akero Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Akero Therapeutics Inc? What does AKRO stand for in stocks?

AKRO is the stock ticker symbol of Akero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akero Therapeutics Inc (AKRO)?

As of Fri Jul 19 2024, market cap of Akero Therapeutics Inc is 1.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers. The fair value of Akero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKRO is over valued or under valued. Whether Akero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKRO.

What is Akero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AKRO's PE ratio (Price to Earnings) is -10.32 and Price to Sales (PS) ratio is 77.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKRO PE ratio will change depending on the future growth rate expectations of investors.